Previous 10 | Next 10 |
Orlando, Florida , May 11, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics Inc. (OTC-PINK: IMUN) (the "Company") announced today that FINRA has processed a reverse split of 1-for 1,000 of the issued and outstanding stock. The reverse stock split was completed with the state of Florida on March...
WINTER PARK, FL, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (Ticker: IMUN) announced today that Cytocom, Inc., a company that spun-off from Immune in 2014, is participating in Biotech Showcase Digital and H.C. Wainwright BioConnect. Both events will be held virtually ...
For Immune Therapeutics ([[IMUN]] +362.0%) the combination of Cytocom and Cleveland BioLabs business means that shareholders who hold a considerable stake in Cytocomcan can realize value.The Cytocom platform technologies and product pipeline, in combination with Cleve...
WINTER PARK, Fla., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Cytocom, Inc. (Cytocom), a leading biopharmaceutical company in the area of immune-modulation, and Cleveland BioLabs, Inc., an innovative biopharmaceutical company developing novel approaches to activate the immune system, today announced...
Cytocom has agreed to reacquire the emerging market rights for its late-stage drug candidates CYTO-201 and CYTO-401, from Immune Therapeutics ( OTCPK:IMUN ) in exchange of up to ~$5M of Immune liabilities. More news on: Immune Therapeutics, Inc., Healthcare stocks news, ...
WINTER PARK, Fla. , Aug. 20, 2020 /PRNewswire/ -- Cytocom, Inc. (Cytocom), a clinical-stage biopharmaceutical company developing novel immune modulating therapies based on proprietary platforms, today announced the company and Immune Therapeutics, Inc. (OTC: IMUN; Immune) have entered i...
Orlando, Florida, July 07, 2020 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC Pink: IMUN) (“Immune” “IMUN” or the “Company”), a biopharmaceutical company focused on the development of therapies for the treatment of Infectious diseases con...
Winter Park, Florida--(Newsfile Corp. - June 9, 2020) - Immune Therapeutics, Inc. (OTC Pink: IMUN), announced today that equity partner, Cytocom, Inc., has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to study CYTO-201 for the treatment...
Winter Park, Florida--(Newsfile Corp. - May 6, 2020) - Immune Therapeutics, Inc. (OTC Pink: IMUN) ("Immune" "IMUN" or the "Company") is a late-stage biopharmaceutical company focused on the development of T-cell activation immunotherapy to treat life-threatening or chronic diseases announced i...
Immune Therapeutics Announces Settlement with Major Creditors as part of licensing agreement Immune Therapeutics Announces Filing of 10K Extension Under SEC Allowance for COVID19 Disruption Forte Aims to Develop and Commercialize Lodonal and IRT=101 for the Treatment of Cancer and ...
News, Short Squeeze, Breakout and More Instantly...
Orlando, FL, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp (OTC Pink: IMUN) (“Biostax”), a hub and spoke biotech development engine, sadly announces the passing of H. Louis Salomonksy, a dedicated member of its Board of Directors. Mr. Salomonksy pas...
Orlando, FL, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp . (OTC Pink: IMUN) (“Biostax”), a hub-and-spoke biotech development engine, announces the signing of a research collaboration agreement with Immgenuity, Inc . The joint resear...
Orlando, FL, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp. (OTC Pink: IMUN) ("Biostax"), a hub-and-spoke biotech development engine, announces that they have accepted the transfer of three Investigational New Drug Applications (IND) for the drug candidate, JKB-12...